期刊
BLOOD ADVANCES
卷 6, 期 9, 页码 2867-2871出版社
ELSEVIER
DOI: 10.1182/bloodadvances.2021006715
关键词
Patients with D30 PR; SD with subsequent conver-sion to CR experience similar early outcomes as patients who achieved CR by D30; ? SUV < sub > max <; sub >?10 may help to identify patients with D30 PR; SD who are at risk for subsequent progression
类别
资金
- University of Texas M.D. Anderson Cancer Center Support Grant from the National Institutes of Health National Cancer Institute [P30 CA016672]
- Lymphoma Research Foundation Career Development Award
- R21 National Institutes of Health grant
For patients with large B-cell lymphoma who achieve partial response or stable disease on day 30 PET-CT scan after receiving axicabtagene ciloleucel treatment, about 70% of them will progress. However, the factors that predict this progression are still unknown. A retrospective study at MD Anderson Cancer Center found that platelet count and maximum standardized uptake volume may be associated with disease progression.
About 70% of patients with large B-cell lymphoma (LBCL) who are treated with axicabtagene ciloleucel (axi-cel) and who achieve a partial response (PR) or stable disease (SD) on the day 30 (D30) positron emission tomography (PET)-computed tomography (CT) scan progress; however, the factors that are predictive of progression are unknown. This a retrospective study of patients with LBCL who were treated with axi-cel at MD Anderson Cancer Center between January of 2018 and February of 2021. Among 50 patients with D30 PR/SD, 13 (26%) converted to a complete response (CR). Among 95 patients with a D30 CR, 72 (76%) remained in CR. On univariate analysis, the only day-5 characteristic associated with conversion from D30 PR/SD to subsequent CR was a higher platelet count (P = .05). The only D30 factor associated with conversion from D30 PR/SD to subsequent CR was a lower maximum standardized uptake volume (SUVmax; P < .001); all patients with D30 SUVmax > 10 progressed. After a median follow-up of 12 months, no significant difference in median progression-free survival was observed between patients who converted from D30 PR/SD to subsequent CR and those who had been in CR since D30 (P = .19). Novel predictive and prognostic markers based on tissue biopsy and noninvasive diagnostic assays are needed to more effectively identify these patients and characterize the biology of their residual disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据